Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug-enabling studies for the treatment of renal cell carcinoma and other cancers. In addition, it is developing other multiple product candidates targeting immuno-oncology applications, which include ARX822, a fab-small molecule bispecific that is in preclinical development for cancers; and ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient's own immune system by targeting the ß and gamma receptors on the cytotoxic T cell. Ambrx Biopharma Inc. has collaborations with Bristol Myers Squibb Company; AbbVie Inc.; BeiGene; Sino Biopharmaceutical Co., Ltd.; NovoCodex; and Elanco Animal Health. The company was incorporated in 2003 and is headquartered in La Jolla, California.

Ambrx Biopharma Inc.

Ambrx develops enhanced antibody-drug conjugates and employs expanded genetic code technology for potential cancer treatments. It focuses on precision biologics innovation.

msh id	COM:AMBRX
symbol	AMAM
name	Ambrx Biopharma Inc.
homepage url	https://ambrx.com
country	US
sector	Healthcare
industry	Biotechnology
market	STOCKS
employee count	87
crunchbase url	-
linkedin url	-
founders	-

market cap	1.77B
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	-2.17
growth cost of revenue	-
growth depreciation and amortization	-0.4
growth ebitda	0.1
growth ebitda ratio	0.1
growth eps	-
growth eps diluted	-
growth general and administrative expenses	0.19
growth gross profit	-0.01
growth gross profit ratio	-

COM:AMBRX

Ambrx

Last Close

27.98

06/03 21:00

Market Cap

1.77B

Beta: -

Volume Today

1.42M

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	-83.83M
cost of revenue	-83.83M
depreciation and amortization	1.29M
ebitda	-55.79M
ebitda ratio	-7.54
eps	-2.02
eps diluted	-2.02
operating expenses	74.14M
operating income	-57.08M
operating income ratio	-7.71

accounts receivables	863K
capital expenditure	-1.05M
cash at beginning of period	170.91M
cash at end of period	56.44M
inventory	3.73M
working capital ttm	215.55M

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-